

TECHNE CORP /MN/

Form 4

March 01, 2006

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**STEER RANDOLPH C**

(Last) (First) (Middle)

**C/O BIOCRYST  
PHARMACEUTICALS, INC, 2190  
PKWY LAKE DRIVE**

(Street)

**BIRMINGHAM, AL 35244**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**TECHNE CORP /MN/ [TECH]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**02/27/2006**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2006		M	10,000	A \$ 52.6565	10,000	D
Common Stock	02/27/2006		M	5,000	A \$ 29.1	15,000	D
Common Stock	02/27/2006		M	5,000	A \$ 30.65	20,000	D
Common Stock	02/27/2006		S	20,000	D \$ 60	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option	\$ 52.6565	02/27/2006		M		10,000		10/09/2000	10/09/2010	Common Stock	10,000
Director Stock Option	\$ 29.1	02/27/2006		M		5,000		10/18/2001	10/18/2011	Common Stock	5,000
Director Stock Option	\$ 30.65	02/27/2006		M		5,000		10/24/2002	10/24/2012	Common Stock	5,000
Director Stock Option	\$ 32.9							10/23/2003	10/23/2013	Common Stock	5,000
Director Stock Option	\$ 37.1							10/21/2004	10/20/2014	Common Stock	5,000
Director Stock Option	\$ 54.68							10/27/2005	10/26/2015	Common Stock	5,000

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
STEER RANDOLPH C C/O BIOCRYST PHARMACEUTICALS, INC 2190 PKWY LAKE DRIVE BIRMINGHAM, AL 35244	X

## Signatures

Randolph C.  
Steer

03/01/2006

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.